MedTrace Logo

PRP Treatment of Osteoarthritic Knee With a New Autologous Blood Product (CytoRich)

NCT03543800 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2018-06-01

No results posted yet for this study

Summary

This study is aimed at evaluating the efficacy and safety of Cytorich compared to platelet-rich plasma (PRP) in alleviating pain and improving function in subjects with knee OA.

Conditions

  • Osteoarthritis of the Knee

Interventions

DEVICE

Cytorich PRP kit

Subjects randomized to the PRP treatment arm will receive PRP only without the anti-inflammatory component of ABP added

DEVICE

PRP kit

PRP kit legally marketed in Canada for PRP

Sponsors & Collaborators

  • Antnor

    lead INDUSTRY

Principal Investigators

  • Ira Brokhman, PhD · Galea Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-02-04
Primary Completion
2019-05-20
Completion
2019-05-20

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03543800 on ClinicalTrials.gov